The University of Southampton
University of Southampton Institutional Repository

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age

Record type: Article

Background: Children are a priority for vaccination in an influenza pandemic, but safety and immunogenicity data for new-generation adjuvanted and whole-virion vaccines are limited.

Objectives:

Immunogenicity
•How does the percentage of children aged 6 months to 12 years of age with a fourfold rise in microneutralisation titres between the prevaccination sample and the sample taken 3 weeks after completion of a two-dose course of the non-adjuvanted, whole-virion vaccine and the AS03B-adjuvanted split-virion vaccine compare?
•How does the percentage of children aged 6 months to 12 years of age with haemagglutination inhibition titres of ? 1 : 32 3 weeks after completion of a two-dose course of the non-adjuvanted, whole-virion vaccine and the AS03B-adjuvanted split-virion vaccine compare?
•How does the percentage of children aged 6 months to 12 years of age with a fourfold rise in haemagglutination inhibition titres between the prevaccination sample and the sample taken 3 weeks after completion of a two-dose course of the non-adjuvanted, whole-virion vaccine and the AS03B-adjuvanted split-virion vaccine compare?
•What is the geometric mean fold rise in haemagglutination inhibition titres from baseline to 3 weeks after two doses of the non-adjuvanted, whole-virion vaccine and the AS03B-adjuvanted split-virion vaccine?
•What is the geometric mean haemagglutination inhibition titre 3 weeks after two doses of the non-adjuvanted, whole-virion vaccine and the AS03B-adjuvanted split-virion vaccine?

Reactogenicity
•How does the percentage of children aged 6 months to 12 years of age experiencing fever and local reactions within the 7 days following each dose of the non-adjuvanted, whole-virion and the AS03B-adjuvanted split-virion vaccines compare?
•What percentage of children aged 6 months to 12 years of age experience non-febrile systemic reactions within the 7 days following each dose of the non-adjuvanted, whole-virion and the AS03B-adjuvanted split-virion vaccine?

Methods: The safety, reactogenicity and immunogenicity of a tocopherol/oil-in-water emulsion-adjuvanted (AS03B) egg culture-derived split-virion H1N1 vaccine and a non-adjuvanted cell culture-derived whole-virion vaccine, given as a two-dose schedule, 21 days apart, were compared in a randomised, open-label trial of children aged 6 months to 12 years of age. Local reactions and systemic symptoms were collected for 1 week post immunisation, and serum was collected at baseline and after the second dose.

Results: Among 937 children receiving vaccine, per-protocol seroconversion rates were higher after the AS03B-adjuvanted vaccine than after the whole-virion vaccine (98.2% vs 80.1% in children < 3 years, 99.1% vs 95.9% among those aged 3–12 years), as were severe local reactions (3.6% vs 0.0% in those under 5 years, and 7.8% vs 1.1% in those aged 5–12 years), irritability in children < 5 years (46.7% vs 32.0%), and muscle pain in older children (28.9% vs 13.2%). The second dose of the adjuvanted vaccine was more reactogenic than the first especially for fever > 38.0°C in those under 5 years of age (8.9% vs 22.4%).

Conclusion: In this first direct comparison of an AS03B-adjuvanted split-virion vaccine versus whole-virion non-adjuvanted H1N1 vaccine, the adjuvanted vaccine – while reactogenic – was more immunogenic, especially in younger children, indicating the potential for improved immunogenicity of influenza vaccines in this age group.

Full text not available from this repository.

Citation

Waddington, C.S., Andrews, N., Hoschler, K., Walker, W.T., Oeser, C., Reiner, A., John, T., Wilkinson, Suzanne, Casey, M., Eccleston, P.E., Allen, R.J., Okike, I., Ladhani, S., Sheasby, E., Waight, P., Collinson, A.C., Heath, P.T,, Finn, A., Faust, S.N., Snape, M.D., Miller, E. and Pollard, A.J. (2010) Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age Health Technology Assessment, 14, (46), pp. 1-130. (PMID:20923610).

More information

Published date: October 2010

Identifiers

Local EPrints ID: 175589
URI: http://eprints.soton.ac.uk/id/eprint/175589
ISSN: 1366-5278
PURE UUID: 4b8f5352-2d21-46a6-ab24-f128d5075357
ORCID for S.N. Faust: ORCID iD orcid.org/0000-0003-3410-7642

Catalogue record

Date deposited: 24 Feb 2011 14:59
Last modified: 18 Jul 2017 12:09

Export record

Contributors

Author: C.S. Waddington
Author: N. Andrews
Author: K. Hoschler
Author: W.T. Walker
Author: C. Oeser
Author: A. Reiner
Author: T. John
Author: Suzanne Wilkinson
Author: M. Casey
Author: P.E. Eccleston
Author: R.J. Allen
Author: I. Okike
Author: S. Ladhani
Author: E. Sheasby
Author: P. Waight
Author: A.C. Collinson
Author: P.T, Heath
Author: A. Finn
Author: S.N. Faust ORCID iD
Author: M.D. Snape
Author: E. Miller
Author: A.J. Pollard

University divisions


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×